GLOW contains GHK-Cu, BPC-157, and a TB component, without KPV. The example formula on this page is 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500: 70 mg total. The formula matters because a draw measured in syringe units does not tell you how much of each peptide it contains.
What Is in a 70 mg GLOW Vial?
| Component | Amount per vial | Concentration in 3 mL |
|---|---|---|
| GHK-Cu | 50 mg | 16.67 mg/mL |
| BPC-157 | 10 mg | 3.33 mg/mL |
| TB component | 10 mg | 3.33 mg/mL |
| Total blend | 70 mg | 23.33 mg/mL |
This matches the amounts in the listed GLOW formula. Blend names are not a universal specification. Check the actual vial label and batch documentation before using any calculation.
The TB name also needs care. Full-length thymosin beta-4 and the shorter fragment called TB-500 are different substances. A trade name alone does not establish which sequence is present. Findings for one form should not automatically be assigned to another.
GLOW Dosage Math: 10, 12, and 15 Units
The table assumes a 70 mg vial mixed with 3.0 mL and a U-100 scale, where 100 units equals 1 mL. Values are rounded. These are separate fixed-draw examples.
| U-100 draw | Volume | BPC-157 | TB component | GHK-Cu | Total blend |
|---|---|---|---|---|---|
| 10 units | 0.10 mL | 333 mcg | 333 mcg | 1.67 mg | 2.33 mg |
| 12 units | 0.12 mL | 400 mcg | 400 mcg | 2 mg | 2.8 mg |
| 15 units | 0.15 mL | 500 mcg | 500 mcg | 2.5 mg | 3.5 mg |
A 12-unit draw gives 25 theoretical draws per vial; a 15-unit draw gives 20. Handling losses can reduce these counts. A draw count is not a storage-life guarantee.
GLOW Blend Calculator
For the 50 / 10 / 10 mg formula only. Change the volume or draw to check the arithmetic.
Calculation only. This tool does not select a dose, establish a schedule, or assess safety.
Example Research Protocol
A community-used example is a fixed 12- or 15-unit draw once daily for 10–12 weeks, using the 70 mg formula mixed with 3 mL. At 12 units, that contains 400 mcg each of BPC-157 and the TB component, plus 2 mg GHK-Cu. At 15 units, it contains 500 mcg of each, plus 2.5 mg GHK-Cu.
The calculations are exact for the stated quantities. The schedule is not established by a controlled human trial of this three-component blend. The sources reviewed here do not establish an optimal GLOW dose, cycle length, or break between cycles. Component studies and community practice should be identified separately.
GLOW vs KLOW: What Changes Without KPV?
For these formulas, KLOW adds 10 mg KPV to the same 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB component. GLOW totals 70 mg; KLOW totals 80 mg.
With both mixed in 3 mL, the shared components stay the same per draw. At 15 units, both contain 500 mcg BPC-157, 500 mcg TB component, and 2.5 mg GHK-Cu. KLOW also contains 500 mcg KPV, bringing its total to 4 mg instead of GLOW’s 3.5 mg.
This explains the arithmetic difference. It does not prove one blend works better, and the evidence reviewed here does not establish a head-to-head clinical advantage.
What Does the Research Actually Show?
Most of the research behind this blend concerns individual components, often in animals or cells. That is useful background, but it does not establish the effects of the finished GLOW blend in people.
- GHK-Cu: a 1993 rat wound-chamber study found increased accumulation of collagen and other extracellular-matrix material. It tested GHK-Cu locally in that model, rather than this blend.
- BPC-157: a 2003 rat Achilles-tendon study reported improved repair measures after tendon transection. Its species, route, and study doses cannot be treated as an established human GLOW protocol.
- Thymosin beta-4: a 1999 rat wound study reported changes in wound closure and tissue repair. The substance tested was thymosin beta-4; the results should not be assigned to an unidentified TB-500 fragment or blend.
No controlled human study of this exact 50 / 10 / 10 mg blend was identified among the sources reviewed for this guide. That is a limit of this review, not a claim that every possible publication has been ruled out.
GLOW Blend vs Separate Components
A blend fixes the ratio. Every extra draw increases all three components together. You cannot raise BPC-157 while holding GHK-Cu steady, or change the TB schedule independently, using one fixed-ratio vial.
Separate components allow a study to vary amounts and timing independently. That flexibility does not establish that a particular separate regimen is safer or more effective. For background, see the BPC-157 and TB-500 comparison and the BPC-157 research overview.
Reconstitution and Storage
Every chart on this page uses 3.0 mL. A different volume changes the concentration: 70 mg in 2 mL would be 35 mg/mL, so the same 15-unit draw would contain 750 mcg each of BPC-157 and the TB component, plus 3.75 mg GHK-Cu.
Confirm the vial contents, diluent, preparation instructions, and batch-specific storage requirements. Follow documented stability and handling guidance for the actual material. Refrigeration and bacteriostatic water do not establish a universal expiry date or guarantee that a blend remains potent and sterile. Do not use a theoretical draw count as evidence of stability.
GLOW Safety: What Is Unknown?
The FDA’s compounding safety information identifies limited human safety data and concerns about peptide impurities and immune reactions for BPC-157 and injectable GHK-Cu. It also distinguishes the TB-500 fragment and notes a lack of identified human-exposure data for that fragment.
The combination’s side-effect rates, long-term effects, and interactions are not established by the component studies cited here. Product identity, contamination, preparation errors, and allergic reactions are separate concerns from the intended biological effects. Research material is not an approved treatment; health decisions belong with a licensed clinician.
GLOW Frequently Asked Questions
Does GLOW contain KPV?
No. The GLOW formula used here contains GHK-Cu, BPC-157, and the TB component. KLOW is the four-component formula that adds KPV.
Why is the total concentration 23.33 mg/mL?
The total vial content is 70 mg. Dividing 70 mg by 3 mL gives 23.33 mg/mL. The 3.33 mg/mL figure applies separately to each 10 mg component.
Does 15 units contain 500 mcg of the whole blend?
No. At 3 mL, 15 units contains 500 mcg each of BPC-157 and the TB component, plus 2.5 mg GHK-Cu. The combined amount is 3.5 mg.
Can I use the same units after changing the mixing volume?
The draw volume would be the same, but the peptide amounts would change. Recalculate each component when either vial content or solution volume changes. The peptide calculator can help check single-component conversions.
The Key Points
For this guide, GLOW is a 70 mg, three-component formula without KPV. At 3 mL, 12 and 15 U-100 units give 400 and 500 mcg of each 10 mg component, with 2 and 2.5 mg GHK-Cu respectively. Those calculations do not establish a validated treatment schedule.
